MedTrace Logo

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

NCT01108458 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-03-03

Study results available
· View outcomes & findings →

Summary

A phase 2 study combining pertuzumab with erlotinib for patients with gemcitabine refractory pancreatic adenocarcinoma

Conditions

Interventions

DRUG

Pertuzumab

iv, 840 mg, 420 mg

DRUG

Erlotinib

PO, 150 mg

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • George Albert Fisher

    lead OTHER

Principal Investigators

  • George Albert Fisher M.D. Ph.D. · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-11-30
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01108458 on ClinicalTrials.gov